Data sourced from ClinicalTrials.gov (NIH registry) Updated weekly IRB-supervised studies only
Home/PA/Reading
Updated September 2026 from ClinicalTrials.gov

Paid Clinical Trials in Reading, PA

Studies commonly pay $75 to $4,500 per completed study

268 clinical trials are currently recruiting participants within 30 miles of Reading. Listings below come straight from the official NIH registry, alongside the area's top-rated research centers with real Google reviews.

268studies recruiting
2+research centers nearby
6condition categories
Live from the NIH registry

Studies recruiting near Reading right now

Top 25 of 268 recruiting studies, sorted by proximity — each links to its official registry page

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Previously Treated Non-Small Cell Lung Cancer Phase 2, Phase 3 Interventional 10,000 participants sought
Penn State Health Saint Joseph Medical Center — Reading, Pennsylvania (0.3 mi) · Sponsor: SWOG Cancer Research Network
See eligibility & contact on ClinicalTrials.gov (NCT03851445)

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Smoldering Plasma Cell Myeloma Phase 3 Interventional 288 participants sought
Reading Hospital — West Reading, Pennsylvania (1.2 mi) · Sponsor: ECOG-ACRIN Cancer Research Group
See eligibility & contact on ClinicalTrials.gov (NCT03937635)

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 Phase 3 Interventional 1,209 participants sought
Reading Hospital — West Reading, Pennsylvania (1.2 mi) · Sponsor: NRG Oncology
See eligibility & contact on ClinicalTrials.gov (NCT05946213)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia Phase 2 Interventional 222 participants sought
Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania (29.5 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT06124157)

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

Bipolar Disorder, Bipolar Depression Phase 3 Interventional 400 participants sought
Lehigh Center for Clinical Research — Allentown, Pennsylvania (29.5 mi) · Sponsor: Xenon Pharmaceuticals Inc.
See eligibility & contact on ClinicalTrials.gov (NCT07172516)

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Percutaneous Coronary Intervention, Peripheral Endovascular Intervention Phase 4 Interventional 6,000 participants sought
Cardiology Associates of West Reading — West Reading, Pennsylvania (1.2 mi) · Sponsor: Duke University
See eligibility & contact on ClinicalTrials.gov (NCT06909565)

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Carcinoma, Transitional Cell, Urinary Bladder Neoplasms Phase 3 Interventional 450 participants sought
Lancaster General Hospital - Ann B Barshinger Cancer Institute — Lancaster, Pennsylvania (28.9 mi) · Sponsor: Eli Lilly and Company
See eligibility & contact on ClinicalTrials.gov (NCT07218380)

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Non-Small Cell Lung Cancer (NSCLC) Phase 3 Interventional 750 participants sought
Lancaster General Hospital — Lancaster, Pennsylvania (28.9 mi) · Sponsor: Bristol-Myers Squibb
See eligibility & contact on ClinicalTrials.gov (NCT07361510)

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

Narcolepsy Type 2 Phase 3 Interventional 176 participants sought
Alkermes Investigational Site — Wyomissing, Pennsylvania (2.2 mi) · Sponsor: Alkermes, Inc.
See eligibility & contact on ClinicalTrials.gov (NCT07502443)

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Multiple conditions Phase 2 Interventional 98 participants sought
Ephrata Cancer Center — Ephrata, Pennsylvania (17.3 mi) · Sponsor: NRG Oncology
See eligibility & contact on ClinicalTrials.gov (NCT06532279)

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Non-small Cell Lung Cancer Phase 3 Interventional 1,000 participants sought
Lancaster General Hospital - Ann B Barshinger Cancer Institute — Lancaster, Pennsylvania (28.9 mi) · Sponsor: Bristol-Myers Squibb
See eligibility & contact on ClinicalTrials.gov (NCT06561386)

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer Phase 3 Interventional 600 participants sought
Reading Hospital - McGlinn Cancer Institute — West Reading, Pennsylvania (1.2 mi) · Sponsor: Hoffmann-La Roche
See eligibility & contact on ClinicalTrials.gov (NCT06793215)

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

Colorectal Cancer Phase 2 Interventional 120 participants sought
UPenn Lancaster-Ann B. Barshinger Cancer Institute — Lancaster, Pennsylvania (28.9 mi) · Sponsor: Criterium, Inc.
See eligibility & contact on ClinicalTrials.gov (NCT06992258)

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer Phase 3 Interventional 1,000 participants sought
The Centers for Advanced Urology d/b/a Keystone Urology Specialist — Lancaster, Pennsylvania (28.9 mi) · Sponsor: Pfizer
See eligibility & contact on ClinicalTrials.gov (NCT07028853)

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis With Cardiomyopathy Phase 3 Interventional 1,750 participants sought
Clinical Trial Site — Lancaster, Pennsylvania (28.9 mi) · Sponsor: Alnylam Pharmaceuticals
See eligibility & contact on ClinicalTrials.gov (NCT07052903)

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm Phase 2 Interventional 335 participants sought
Reading Hospital — West Reading, Pennsylvania (1.2 mi) · Sponsor: National Cancer Institute (NCI)
See eligibility & contact on ClinicalTrials.gov (NCT05554406)

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

Urinary Bladder Neoplasms, Neoplasm Metastasis Phase 1 Interventional 677 participants sought
Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute — Lancaster, Pennsylvania (28.9 mi) · Sponsor: Eli Lilly and Company
See eligibility & contact on ClinicalTrials.gov (NCT05614739)

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma Phase 3 Interventional 1,450 participants sought
Penn State Health Saint Joseph Medical Center — Reading, Pennsylvania (0.3 mi) · Sponsor: ECOG-ACRIN Cancer Research Group
See eligibility & contact on ClinicalTrials.gov (NCT04566328)

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer Phase 2, Phase 3 Interventional 626 participants sought
Local Institution - Unk041 — Allentown, Pennsylvania (29.5 mi) · Sponsor: Mirati Therapeutics Inc.
See eligibility & contact on ClinicalTrials.gov (NCT04613596)

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Psychosis Associated With Alzheimer's Disease Phase 3 Interventional 410 participants sought
Local Institution - 1019 — Allentown, Pennsylvania (29.5 mi) · Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See eligibility & contact on ClinicalTrials.gov (NCT05511363)

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8 Phase 3 Interventional 228 participants sought
Geisinger Cancer Services-Pottsville — Pottsville, Pennsylvania (27.7 mi) · Sponsor: Alliance for Clinical Trials in Oncology
See eligibility & contact on ClinicalTrials.gov (NCT06992427)

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver Disease Phase 3 Interventional 4,500 participants sought
US Digestive Health - Wyomissing — Wyomissing, Pennsylvania (2.2 mi) · Sponsor: Eli Lilly and Company
See eligibility & contact on ClinicalTrials.gov (NCT07165028)

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

Cardiovascular Risk, Acute Myocardial Infarction (AMI) Phase 3 Interventional 10,000 participants sought
Reading Hospital — West Reading, Pennsylvania (1.2 mi) · Sponsor: Novo Nordisk A/S
See eligibility & contact on ClinicalTrials.gov (NCT06118281)
Actively enrolling

Studies you may be able to join near Reading

These studies are recruiting through partner research networks. We may be paid a referral fee if you complete their screening form — this never changes what you pay (nothing) or the compensation the study offers you.

See which clinical studies you may qualify for

A partner research network matches volunteers with studies that are currently enrolling in the United States. You answer a few screening questions about your health and where you live; if a study looks like a fit, its team contacts you to confirm eligibility.

Screening is free and takes a few minutes. Eligibility and any compensation are confirmed by the study team, not by this site.

Check your eligibility
Google-rated

Top-rated research centers in Reading

Dedicated clinical research sites near you — with their real Google ratings, reviews and contact details

Clinical Research Center-Reading

2760 Century Blvd #3, Reading, PA 19610
(610) 375-2466

Lehigh Center for Clinical Research

★ 5.0
1245 S Cedar Crest Blvd, Allentown, PA 18103
(610) 820-0342
"Staff was very friendly and explained information to me in great detail"
— Virgilio Baello, 5★

Clinical trials in Reading: what's recruiting

The Reading area currently has 268 studies open to new participants, according to the ClinicalTrials.gov registry maintained by the U.S. National Institutes of Health. Among the studies closest to Reading, the most active research areas are:

  • Cancer & Oncology15 studies
  • Heart & Vascular3 studies
  • Brain & Mental Health2 studies
  • Immune & Skin1 studies
  • Diabetes & Metabolism1 studies

Every listing shows the study phase, the recruiting site and its distance from Reading, and links to the official registry page where eligibility criteria and study contacts are published. Compensation is set by each sponsor: industry surveys report typical payments of $75 to $4,500 per completed study, with short observational studies at the low end and multi-visit or overnight Phase 1 studies at the high end.

How to enroll in a paid study in Reading

Start with a study whose condition matches your profile — or a healthy-volunteer study if you have no diagnosis. Contact the research site through the registry page, complete a short phone screen, then attend an in-person screening visit. If you qualify, the study team walks you through the informed consent document, which details every procedure, risk and payment before you commit. You can withdraw at any point, and enrollment is always free.

Reading participants can also register with the dedicated research centers listed above — many maintain volunteer databases and call when a matching study opens — or sign up for our email alert below to hear when a new study starts recruiting within 30 miles of your ZIP code.

Frequently asked questions

How much do paid clinical trials in Reading pay?
Compensation varies by study length, procedures and overnight stays. Industry surveys report typical payments from $75 to $4,500 per completed study, with simple observational studies at the low end and multi-week inpatient Phase 1 studies at the high end. Each listing's study team will confirm the exact amount before you enroll.
Do I need to be sick to join a clinical trial in Reading?
No. Many studies recruit healthy volunteers, especially early-phase studies run at dedicated research centers. Others need participants diagnosed with a specific condition. Every trial lists its eligibility criteria — age range, condition, medications — and the study team screens you before enrollment.
Are clinical trials in Reading safe?
Every trial on this page is registered on ClinicalTrials.gov, the official NIH registry, and is overseen by an Institutional Review Board (IRB). Before joining you receive an informed consent document detailing procedures, risks and compensation. Participation is voluntary and you can withdraw at any time.
How do I join a study in Reading, PA?
Pick a study that matches your profile, contact the research site (or apply through the study links on this page), pass a phone pre-screen, then attend an in-person screening visit. If you qualify, you review and sign the informed consent and the study begins. The process typically takes 1-3 weeks.
What is the difference between a research center and a hospital study in Reading?
Dedicated research centers (listed on this page with their Google ratings) run studies as their core business — often healthy-volunteer and vaccine studies with structured compensation. Hospital and university studies tend to focus on patients with specific conditions. Both types are registered and IRB-supervised.

Paid clinical trials near Reading

Other metros within reach

Lancaster, PA420 Allentown, PA229 Philadelphia, PA2,171 York, PA441 Harrisburg, PA399 Scranton, PA92 Trenton, NJ2,340 Baltimore, MD1,651

By condition

Eligibility and exclusions, condition by condition

Alcoholic Liver Disease in Reading Chronic Kidney Disease (HealthMatch) in Reading Bladder Issues Due To Spinal Cord Injury in Reading All conditions

More of PA

Philadelphia2,171 Pittsburgh1,237 York441 Lancaster420 Harrisburg399 Allentown229 Scranton92 Erie90

New paid studies open every week

Get an email when a new clinical trial starts recruiting within 30 miles of your ZIP code. No spam — only real studies from the NIH registry.

By subscribing you agree to receive study alert emails. Unsubscribe anytime in one click.

Get free trial alerts